Study suggests blood test could detect severe CTE in living people, but is early-stage
A JAMA study of 21 former football players found a blood biomarker, eMTBR-tau, was elevated in severe CTE confirmed after death. Researchers say the finding is preliminary and needs larger validation.
1 / 2
The story, neutrally told
Mixed · 2Researchers led by Boston University and Banner Health reported a blood-based method that could help identify chronic traumatic encephalopathy (CTE) in living people, a disease that can currently be confirmed only by examining brain tissue after death. New York PostR “A research team led by Boston University and Banner Health examined 21 former American football players.” Read at New York Post ↗ Scientific AmericanLC “it currently can only be diagnosed by autopsy after a person dies” Read at Scientific American ↗ Mixed · 2The study, published in the Journal of the American Medical Association on Thursday, analysed blood samples from 21 football players who donated their brains to science; 18 of them were found to have CTE at varying stages. Scientific AmericanLC “researchers analyzed blood samples from 21 football players who donated their brains to science, 18 of whom were found to have varying stages of CTE after their deaths” Read at Scientific American ↗ New York PostR “Of the samples, 18 (85%) had CTE, or chronic traumatic encephalopathy. Of these, 16 (88%) had more severe (stage 3 or 4) CTE.” Read at New York Post ↗ Mixed · 2The test looks for a biomarker called endogenously cleaved microtubule-binding region tau (eMTBR-tau), which reflects tangled tau protein in the brain. Levels were significantly higher in higher-stage CTE but not in low-stage CTE or in people without CTE, so the biomarker identified the most severe cases. New York PostR “eMTBR-tau levels were significantly higher in higher stage CTE, but weren’t higher in people with low stage CTE or no CTE.” Read at New York Post ↗ Scientific AmericanLC “specific biomarkers found in their blood could identify the most severe CTE cases” Read at Scientific American ↗
Mixed · 2Because eMTBR-tau is also elevated in Alzheimer's disease, Michael Alosco, the senior author and co-director of clinical research at Boston University's CTE Center, said a second biomarker, p-tau217, which tracks closely with Alzheimer's but not CTE, could be used alongside it in a two-part test to tell the diseases apart. Some of the players had both CTE and Alzheimer's, and had the highest eMTBR-tau levels. Scientific AmericanLC “it is known to “track closely” with Alzheimer’s—but not with CTE, Alosco says. In theory, a two-part blood test for both biomarkers could identify patients with CTE.” Read at Scientific American ↗ New York PostR “Levels of eMTBR-tau were highest among these people.” Read at New York Post ↗ Mixed · 2The authors stress the work is preliminary. Alosco said the team is "still in the discovery phase" with a small sample, and the test is not approved by the US Food and Drug Administration. The New York Post reports that future research will need hundreds more participants, including people at varying CTE stages and people with Alzheimer's. New York PostR ““We are still in the discovery phase and it’s a small sample size, but if future studies validate these findings”“research will need to look at hundreds more participants at varying stages of CTE and who have Alzheimer’s.” Read at New York Post ↗ Scientific AmericanLC “The test is not approved by the U.S. Food and Drug Administration, cautions Michael Alosco” Read at Scientific American ↗ Mixed · 2If validated, researchers say it could open the way to clinical trials of treatments in living patients and help establish how common CTE is in the general population. There is currently no treatment for CTE, though doctors can ease symptoms. Scientific AmericanLC “It could also lead to better designed clinical trials to test therapeutics for CTE in living people” Read at Scientific American ↗ New York PostR “There is no treatment for CTE, and it gets worse over time.” Read at New York Post ↗
Mixed · 2Outside experts and co-authors welcomed the result. Michael Buckland of the University of Sydney, who was not involved, called it "a watershed moment for the field" while noting there is "still a long way to go" before clinical validation. Co-author Nicholas Ashton said a blood test "has been revolutionary" for Alzheimer's and he is optimistic the same will be true for CTE. Scientific AmericanLC ““It is a watershed moment for the field, demonstrating that fluid biomarkers can work in assisting diagnosis of CTE in the living,””“While there is still a long way to go before the test can be validated for clinical use” Read at Scientific American ↗ New York PostR “Nicholas Ashton, another author on the study, points out that a blood test “has been revolutionary” in diagnosing and treating Alzheimer’s disease.” Read at New York Post ↗ Left · 1Scientific American adds that the study came days after another JAMA paper, using mass spectrometry, found eMTBR-tau elevated in patients with severe tau-related diseases including Alzheimer's and CTE. Scientific AmericanLC “The study comes days after the publication of another paper, also in JAMA, in which researchers using mass spectrometry found that eMTBR-tau was elevated” Read at Scientific American ↗
Every sentence links to the reporting it rests on. The pill in front of each says where its sources sit: Left, Centre or Right when one side supplies at least half of them, Mixed when they are evenly split. The number is how many outlets it cites.
Left1 outlet
- Framing
- Measured science report: a first-of-its-kind test that may be 'just around the corner' but depends on validation in large studies.
- Emphasis
- Study limits (small sample, no FDA approval), the Alzheimer's confound and the two-biomarker approach, and an independent expert's view.
- Leaves out or plays down
- Does not give the stage breakdown, the NFL prevalence figure or the symptom and symptom-management detail.
- Charged language
- “watershed moment”
- For example
-
“A first-of-its-kind blood test for chronic traumatic encephalopathy (CTE) may be just around the corner.” — Scientific American
“given the small sample size of the study, more research is needed to confirm the findings” — Scientific American
Centre0 outlets
No centre outlet in our sources has covered this story yet.
Right1 outlet
- Framing
- Consumer-health angle opening on a 'game changer' for living patients and NFL players, with caveats later in the piece.
- Emphasis
- Prevalence among NFL players, symptoms, subgroup counts by playing level, and symptom management options.
- Leaves out or plays down
- Includes no independent outside expert and doesn't mention the lack of FDA approval or the p-tau217 two-part approach.
- Charged language
- “game changer”“groundbreaking innovation”“before it’s too late”
- For example
-
“A simple blood test could identify CTE in living patients — a groundbreaking innovation” — New York Post
“Recent research has found that as many as 1 in 4 NFL players develop CTE” — New York Post
What every side reports
- The study analysed blood from 21 former football players who later donated their brains; 18 had CTE.
- CTE can currently be confirmed only after death.
- The biomarker eMTBR-tau was elevated in severe CTE.
- The test is not validated; larger studies are needed.
- Michael Alosco of Boston University's CTE Center is quoted.
Where accounts differ
-
How to characterise the result
- Left
- Scientific American leads with the caveat that the test is 'if validated in larger trials' and quotes an outside expert's 'watershed moment' alongside the FDA and sample-size cautions.
- Right
- The New York Post leads with 'game changer' and the prospect of NFL players getting treatment 'before it's too late', adding the caveats later.
Chronic traumatic encephalopathy topic
CTE is a neurodegenerative disease linked to repeated head trauma that currently can be diagnosed only after death; both outlets present the new blood biomarker as a possible route to diagnosis in life, pending validation.
“CTE is a devastating neurodegenerative disease linked to repeated head trauma” — Scientific American
“The only currently proven way to detect CTE is by extracting and examining a person’s brain tissue from their dead body.” — New York Post
Left1 article
-
‘A watershed moment’: Researchers unveil first-of-its-kind blood test for CTE
Mixed Optimistic but cautious science news that foregrounds validation needs and an independent expert's comment.

Centre0 articles
No coverage yet.
Right1 article
-
‘Game changer’ blood test could detect CTE in living patients for the first time
Celebratory Enthusiastic health report leading with 'game changer' and patient benefit, with limitations noted further down.

- 19 Nov 18:50 First New York PostR ‘Game changer’ blood test could detect CTE in living patients for the first time
- 19 Nov 18:50 First Scientific AmericanLC ‘A watershed moment’: Researchers unveil first-of-its-kind blood test for CTE
Times are when each article was published, or when we first saw it if the outlet gave no time.
Ask about this story
Loading…